IBS-C vs IBS-D: How Symptoms and Treatment Differ

IBS-C vs IBS-D is more than a labeling detail. Irritable bowel syndrome affects an estimated 12% of people worldwide PMID: 29072609, and two people with the same diagnosis can have opposite problems: one struggles with hard, infrequent stools and a painful, bloated belly, while the other rushes to the bathroom several times a morning. The first likely has IBS with constipation (IBS-C) and the second IBS with diarrhea (IBS-D), and that subtype quietly changes which tests make sense and which treatments are worth trying.

This guide explains how to work out your subtype, why it can change, where IBS ends and plain constipation or diarrhea begins, and how testing and treatment split by subtype, with the actual trial numbers. For a ranked look at non-prescription options across all subtypes, see our guide to IBS treatments that actually work.

This article is for general education and isn't a substitute for advice from your own doctor.

How Do I Know If I Have IBS-C or IBS-D?

The Rome IV criteria, written by an international expert committee, are the current standard for diagnosing functional bowel disorders. They separate these conditions into distinct categories: irritable bowel syndrome, functional constipation, functional diarrhea, functional bloating, and unspecified functional bowel disorder PMID: 27144627. Abdominal pain is essential to IBS. Without it the diagnosis doesn't hold, and a careful history, a check for warning signs, and a guided physical exam come before the label PMID: 29072609.

Once IBS is diagnosed, Rome IV assigns a subtype based on which stool form predominates on the days when bowel movements are abnormal PMID: 27144627. In studies and in clinic, stool form is recorded with the 7-point Bristol Stool Form Scale, often in a daily diary PMID: 22176384.

• IBS-C (constipation-predominant): hard or lumpy stools (Bristol types 1 and 2) predominate on abnormal days.
• IBS-D (diarrhea-predominant): mushy or watery stools (Bristol types 6 and 7) predominate on abnormal days.
• IBS-M (mixed): both hard and loose stools are common.
• IBS-U (unclassified): bowel habits don't fit any of the patterns above.

Work out your subtype with a 2-week stool diary

How you report symptoms changes the answer. In a study of 126 people with IBS, subtypes based on recalled symptoms matched subtypes based on prospective diaries only 41% to 51% of the time, even under the same classification system PMID: 22420629. A diary is more reliable than memory, and two weeks beats one: two weeks of diary data increased the share of people with a stable, predominant subtype PMID: 22176384.

1. Record every bowel movement for 14 days. Note the date, time, and Bristol type (1 to 7).
2. Mark the abnormal ones. Types 1 and 2 count as hard; types 6 and 7 count as loose. Types 3 to 5 fall in between.
3. Add a pain score. Rate abdominal pain from 0 to 10 each day, since pain is what separates IBS from functional constipation or diarrhea.
4. Count the pattern. Tally how many abnormal movements were hard versus loose. Mostly hard points toward IBS-C, mostly loose toward IBS-D, and plenty of both toward IBS-M.
5. Bring the diary to your appointment. Your doctor applies the formal Rome IV cutoffs and checks for anything that needs testing first.

What is IBS-M?

IBS-M, or mixed IBS, means both hard and loose stools show up regularly. It's the least stable subtype over time PMID: 34927758, which is why people with IBS-M often notice their pattern leaning toward constipation for a while, then toward diarrhea. If your pattern is mixed, tell your doctor before starting a laxative or an antidiarrheal.

Can IBS Switch From Constipation to Diarrhea?

Yes, and it's common. In a study of 126 people who recorded every bowel movement on the Bristol scale for 10 weeks, only 18% to 35% kept the same subtype every week. Still, 82% to 98% had one predominant subtype at least 60% of the time, and 69% had the same predominant subtype as at baseline, which suggests a stable tendency beneath the week-to-week noise PMID: 22176384.

Longer-term data tell the same story. A review of IBS natural history reported that, in one clinical trial cohort, only about one in four patients kept their baseline classification throughout, two in three moved between IBS-C and IBS-M, and over half moved between IBS-D and IBS-M. Across population studies, 17% to 55% of people reported their symptoms resolving over time PMID: 34927758.

The practical takeaway: if a treatment that once worked starts to fail, or starts causing the opposite problem, your subtype may have shifted. That's a reason to repeat the stool diary and revisit the plan with your doctor, not simply to take more of the same medication.

IBS-C vs Chronic Constipation, and IBS-D vs Functional Diarrhea

IBS-C and functional constipation look alike, as do IBS-D and functional diarrhea. The main dividing line in Rome IV is pain: IBS involves frequent abdominal pain, while functional constipation and functional diarrhea are relatively painless. In a study of 567 patients classified by Rome IV, people with IBS had clinically abnormal anxiety more often (38% vs 20%) and depression more often (17% vs 10%) than people with functional constipation or diarrhea, and these scores rose with how often pain occurred. There were no differences between individual IBS subtypes PMID: 33719130.

The boundary is blurry in practice. When the developers of the Rome IV diagnostic questionnaire allowed IBS and functional constipation to overlap, the questionnaire's sensitivity for functional constipation rose from 32.2% to 73.2%, and Rome IV diagnoses were reproducible in about three-quarters of patients after one month PMID: 27144634.

If constipation is your main problem and pain is rare, the approaches in our constipation relief guide may fit better than an IBS-specific plan. If pain is frequent, the Rome IV study authors suggest considering psychological therapies early in the course, whichever bowel pattern you have PMID: 33719130.

Tests Your Doctor May Order

IBS is meant to be diagnosed positively, based on symptoms and targeted testing, rather than by running every possible test first. The American College of Gastroenterology (ACG) guideline suggests this positive diagnostic strategy over a strategy of exclusion, because it gets people to appropriate treatment sooner PMID: 33315591.

Diarrhea symptoms change the testing picture. The ACG suggests blood testing for celiac disease in people with IBS and diarrhea symptoms, and a fecal calprotectin test in people with suspected IBS and diarrhea symptoms to rule out inflammatory bowel disease PMID: 33315591. A doctor may also consider bile acid malabsorption. In a meta-analysis of six studies with 908 people meeting criteria for IBS-D, the pooled rate of bile acid malabsorption on a specialized scan was 28.1% PMID: 25913530.

For constipation-predominant symptoms, testing is guided more by age, alarm features, and history than by a routine panel. The warning signs covered below call for fuller evaluation with either subtype.

IBS-C vs IBS-D at a Glance

How Treatment Differs by Subtype

Treatments that help both subtypes

Several treatments target IBS as a whole rather than one bowel pattern, and they're reasonable starting points for either subtype.

Low-FODMAP diet. The ACG recommends a limited trial of a low-FODMAP diet to improve global IBS symptoms PMID: 33315591. It's a short elimination and reintroduction process, not a permanent diet; our low-FODMAP diet guide walks through the phases, and our list of foods that commonly cause bloating is a useful companion if gas and distension are your worst symptoms.

Peppermint oil. A meta-analysis of 12 randomized trials with 835 patients found peppermint oil more than doubled the chance of global symptom improvement versus placebo (risk ratio 2.39) and improved abdominal pain (risk ratio 1.78). The number needed to treat was three for global symptoms and four for pain, and side effects didn't differ significantly from placebo PMID: 30654773. Because it targets cramping and pain rather than stool pattern, it isn't tied to one subtype.

Gut-directed psychological therapy. The ACG suggests gut-directed psychotherapy for global IBS symptoms PMID: 33315591. A network meta-analysis of 41 randomized trials with 4,072 participants found cognitive behavioral therapy and gut-directed hypnotherapy had the largest evidence base and the most lasting benefit, though the risk of bias was high and effects may be overestimated PMID: 32276950.

Best treatment for IBS-C

Psyllium. In a 12-week randomized trial of 275 people with IBS in primary care (not limited to IBS-C), 57% of people taking psyllium had adequate relief in the first month versus 35% on placebo, and 59% versus 41% in the second month. After three months, symptom severity fell by 90 points with psyllium versus 49 with placebo. Bran didn't reliably beat placebo, and early dropouts in the bran group were mostly due to worsening symptoms PMID: 19713235. Our fiber supplements guide compares psyllium products with other fiber types.

Polyethylene glycol (PEG). In a 4-week randomized trial of 139 people with IBS-C, PEG with electrolytes raised weekly spontaneous bowel movements to 4.40 versus 3.11 on placebo in the final week, and improved stool consistency and straining. Abdominal pain improved from baseline, but no more than it did on placebo PMID: 23835436. The American Gastroenterological Association (AGA) makes a conditional recommendation for PEG in IBS-C, based on low-certainty evidence PMID: 35738724. It can help the constipation, but may not help the pain that defines IBS. We don't rank laxatives here.

Prescription options to discuss with a doctor. The ACG recommends chloride channel activators (such as lubiprostone) and guanylate cyclase activators (such as linaclotide and plecanatide) for global IBS-C symptoms PMID: 33315591. The AGA's 2022 guideline makes a strong recommendation for linaclotide (high-certainty evidence) and conditional recommendations for tenapanor, plecanatide, tegaserod, and lubiprostone (moderate certainty), and it recommends against SSRIs for IBS-C PMID: 35738724.

• Linaclotide: in a 26-week trial of 804 people with IBS-C, 33.7% met the FDA's combined pain-and-bowel-movement response goal versus 13.9% on placebo, a number needed to treat of about 5. Diarrhea led 4.5% of people taking it to stop, versus 0.2% on placebo PMID: 22986437.
• Tegaserod: reapproved in the US for women younger than 65 without a history of cardiovascular ischemic events. In pooled data from four trials, 44.1% of that group responded versus 36.5% on placebo PMID: 34047303.

All of these need a prescription and a conversation about side effects, cost, and whether they fit your history.

Best treatment for IBS-D

Loperamide. Loperamide (Imodium) slows the gut and is widely used for IBS-D, but it's a stool-control tool, not a treatment for IBS as a whole. In a small crossover trial of 28 people with IBS, diarrhea, urgency, and rumbling improved further on loperamide than on placebo, driven by fewer and more formed stools, but abdominal pain was not among the symptoms that improved beyond placebo PMID: 6365490. A larger 5-week trial found improved stool consistency (32%), fewer bowel movements (36%), and less overall pain intensity, but also more abdominal pain at night PMID: 8734343. The AGA gives loperamide a conditional recommendation in IBS-D with very low certainty of evidence PMID: 35738725. It's reasonable for controlling stool frequency on bad days, but don't count on it for cramping, and stop if you become constipated.

Probiotics. Probiotic evidence is strain-specific and mixed; if you want to try one, our guides to the best probiotics for IBS and the best probiotics for diarrhea separate the studied strains from the rest.

Prescription options to discuss with a doctor. The AGA's 2022 guideline makes conditional recommendations for eluxadoline, rifaximin, and alosetron (moderate certainty), and for tricyclic antidepressants and antispasmodics (low certainty), and recommends against SSRIs for IBS-D PMID: 35738725.

• Rifaximin: a minimally absorbed antibiotic taken as a 2-week course. In two phase 3 trials of people with IBS without constipation, 40.7% had adequate relief of global symptoms in the month after treatment versus 31.7% on placebo, with bloating relief in 40.2% versus 30.3%, and similar side effect rates PMID: 21208106. The ACG recommends it for global IBS-D symptoms PMID: 33315591. It's also used for small intestinal bacterial overgrowth, which our SIBO guide covers.
• Eluxadoline: acts on opioid receptors in the gut. In two phase 3 trials of 2,427 adults with IBS-D, 25% to 30% of people on the higher dose improved on both pain and stool consistency over 12 weeks, versus 16% to 17% on placebo. Pancreatitis occurred in 5 of 1,666 patients (0.3%) PMID: 26789872.
• Alosetron: prescribed under a formal risk management program because of rare but serious side effects. Over nine years of that program, ischemic colitis occurred at about 1 case per 1,000 patient-years and serious complications of constipation at 0.25 per 1,000 PMID: 24003335.
• Bile acid binders: if testing points to bile acid malabsorption, the approach changes. A systematic review of 18 studies found response to the binder colestyramine in 96% of people with severe malabsorption, 80% with moderate, and 70% with mild PMID: 19570102.

Which approach fits your main symptom?

Putting It Together

A sensible sequence starts the same way for either subtype: confirm the diagnosis, check for warning signs, and get any subtype-appropriate tests. Then try one or two shared approaches, matched to your worst symptom, and add subtype-specific tools if needed.

Two cautions apply. First, track symptoms with a diary so you can tell whether a change is helping, especially since subtypes drift over time PMID: 34927758. Second, a treatment that controls stool pattern without touching pain, such as PEG in IBS-C PMID: 23835436 or loperamide in IBS-D PMID: 6365490, may leave the core IBS symptom unaddressed.

Red Flags: When to See a Doctor Promptly

IBS-type symptoms don't rule out other conditions. Warning signs include anemia, blood in the stool, unintentional weight loss, and a family history of colorectal cancer or inflammatory bowel disease PMID: 29072609. Fever, symptoms that wake you from sleep, and new or changing bowel habits later in life are also reasons to see a doctor promptly. Ongoing diarrhea specifically warrants the celiac and fecal calprotectin testing described above PMID: 33315591. If you're due for colorectal cancer screening, our at-home colon cancer screening guide explains the options, but a home test doesn't replace an evaluation when you have alarm symptoms.

Frequently Asked Questions

What is the difference between IBS-C and IBS-D? Both are subtypes of irritable bowel syndrome, which requires recurring abdominal pain linked to changes in bowel habits. In IBS-C, hard or lumpy stools predominate on abnormal days; in IBS-D, loose or watery stools predominate. The subtype changes which tests a doctor may order and which medications are likely to help.

How do I know if I have IBS-C or IBS-D? A doctor assigns the subtype using Rome IV, based on which stool form predominates on abnormal days, usually recorded with the Bristol Stool Form Scale. A two-week stool diary gives a more stable picture than one week.

Can IBS switch from constipation to diarrhea? Yes. Only 18% to 35% of people in a 10-week diary study kept the same subtype every week, though most had one predominant pattern. Long-term data show frequent movement between IBS-C, IBS-D, and IBS-M.

What is IBS-M? Mixed IBS, where both hard and loose stools are common. It's the least stable subtype, so the pattern often leans one way, then the other.

Is IBS-C the same as chronic constipation? They overlap but aren't identical. Under Rome IV, IBS requires frequent abdominal pain, while functional constipation and functional diarrhea are relatively painless.

What is the best treatment for IBS-D? There's no single best option. The ACG recommends rifaximin, and the AGA conditionally recommends eluxadoline, rifaximin, and alosetron. Loperamide can reduce stool frequency but isn't a reliable pain treatment.

What is the best treatment for IBS-C? The AGA strongly recommends linaclotide and conditionally recommends plecanatide, lubiprostone, tenapanor, tegaserod, and PEG. PEG helps bowel movements but didn't beat placebo for pain in a trial. Psyllium, peppermint oil, and gut-directed therapy are reasonable non-prescription steps.

References

1. Lacy BE, Patel NK. Rome Criteria and a Diagnostic Approach to Irritable Bowel Syndrome. Journal of Clinical Medicine. 2017;6(11):99. PMID: 29072609.
2. Mearin F, Lacy BE, Chang L, et al. Bowel Disorders. Gastroenterology. 2016;S0016-5085(16)00222-5. PMID: 27144627.
3. Engsbro AL, Simren M, Bytzer P. Short-term stability of subtypes in the irritable bowel syndrome: prospective evaluation using the Rome III classification. Alimentary Pharmacology & Therapeutics. 2012;35(3):350-359. PMID: 22176384.
4. Engsbro AL, Simrén M, Bytzer P. The Rome II and Rome III criteria identify the same subtype-populations in irritable bowel syndrome: agreement depends on the method used for symptom report. Neurogastroenterology & Motility. 2012;24(7):604-611. PMID: 22420629.
5. Yadav YS, Eslick GD, Talley NJ. Review article: irritable bowel syndrome: natural history, bowel habit stability and overlap with other gastrointestinal disorders. Alimentary Pharmacology & Therapeutics. 2021;54(Suppl 1):S24-S32. PMID: 34927758.
6. Shiha MG, Asghar Z, Thoufeeq M, et al. Increased psychological distress and somatization in patients with irritable bowel syndrome compared with functional diarrhea or functional constipation, based on Rome IV criteria. Neurogastroenterology & Motility. 2021;33(10):e14121. PMID: 33719130.
7. Palsson OS, Whitehead WE, van Tilburg MA, et al. Rome IV Diagnostic Questionnaires and Tables for Investigators and Clinicians. Gastroenterology. 2016;S0016-5085(16)00180-3. PMID: 27144634.
8. Lacy BE, Pimentel M, Brenner DM, et al. ACG Clinical Guideline: Management of Irritable Bowel Syndrome. American Journal of Gastroenterology. 2021;116(1):17-44. PMID: 33315591.
9. Slattery SA, Niaz O, Aziz Q, et al. Systematic review with meta-analysis: the prevalence of bile acid malabsorption in the irritable bowel syndrome with diarrhoea. Alimentary Pharmacology & Therapeutics. 2015;42(1):3-11. PMID: 25913530.
10. Alammar N, Wang L, Saberi B, et al. The impact of peppermint oil on the irritable bowel syndrome: a meta-analysis of the pooled clinical data. BMC Complementary and Alternative Medicine. 2019;19(1):21. PMID: 30654773.
11. Black CJ, Thakur ER, Houghton LA, et al. Efficacy of psychological therapies for irritable bowel syndrome: systematic review and network meta-analysis. Gut. 2020;69(8):1441-1451. PMID: 32276950.
12. Bijkerk CJ, de Wit NJ, Muris JW, et al. Soluble or insoluble fibre in irritable bowel syndrome in primary care? Randomised placebo controlled trial. BMJ. 2009;339:b3154. PMID: 19713235.
13. Chapman RW, Stanghellini V, Geraint M, et al. Randomized clinical trial: macrogol/PEG 3350 plus electrolytes for treatment of patients with constipation associated with irritable bowel syndrome. American Journal of Gastroenterology. 2013;108(9):1508-1515. PMID: 23835436.
14. Chang L, Sultan S, Lembo A, et al. AGA Clinical Practice Guideline on the Pharmacological Management of Irritable Bowel Syndrome With Constipation. Gastroenterology. 2022;163(1):118-136. PMID: 35738724.
15. Chey WD, Lembo AJ, Lavins BJ, et al. Linaclotide for irritable bowel syndrome with constipation: a 26-week, randomized, double-blind, placebo-controlled trial to evaluate efficacy and safety. American Journal of Gastroenterology. 2012;107(11):1702-1712. PMID: 22986437.
16. Shah ED, Lacy BE, Chey WD, et al. Tegaserod for Irritable Bowel Syndrome With Constipation in Women Younger Than 65 Years Without Cardiovascular Disease: Pooled Analyses of 4 Controlled Trials. American Journal of Gastroenterology. 2021;116(8):1601-1611. PMID: 34047303.
17. Cann PA, Read NW, Holdsworth CD, et al. Role of loperamide and placebo in management of irritable bowel syndrome (IBS). Digestive Diseases and Sciences. 1984;29(3):239-247. PMID: 6365490.
18. Efskind PS, Bernklev T, Vatn MH. A double-blind placebo-controlled trial with loperamide in irritable bowel syndrome. Scandinavian Journal of Gastroenterology. 1996;31(5):463-468. PMID: 8734343.
19. Lembo A, Sultan S, Chang L, et al. AGA Clinical Practice Guideline on the Pharmacological Management of Irritable Bowel Syndrome With Diarrhea. Gastroenterology. 2022;163(1):137-151. PMID: 35738725.
20. Pimentel M, Lembo A, Chey WD, et al. Rifaximin therapy for patients with irritable bowel syndrome without constipation. New England Journal of Medicine. 2011;364(1):22-32. PMID: 21208106.
21. Lembo AJ, Lacy BE, Zuckerman MJ, et al. Eluxadoline for Irritable Bowel Syndrome with Diarrhea. New England Journal of Medicine. 2016;374(3):242-253. PMID: 26789872.
22. Tong K, Nicandro JP, Shringarpure R, et al. A 9-year evaluation of temporal trends in alosetron postmarketing safety under the risk management program. Therapeutic Advances in Gastroenterology. 2013;6(5):344-357. PMID: 24003335.
23. Wedlake L, A'Hern R, Russell D, et al. Systematic review: the prevalence of idiopathic bile acid malabsorption as diagnosed by SeHCAT scanning in patients with diarrhoea-predominant irritable bowel syndrome. Alimentary Pharmacology & Therapeutics. 2009;30(7):707-717. PMID: 19570102.